Drug
Trifluridine Tipiracil
Trifluridine Tipiracil: highest development phase Phase 3, developed by Servier. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| Trifluridine/Tipiracil NCT04737187 | Phase 3 | Refractory Metastatic Colorectal Cancer |
| Trifluridine/Tipiracil hydrochloride (S95005) NCT03306394 | Phase 3 | Metastatic Colorectal Cancer |
| Trifluridine/Tipiracil NCT04894123 | Phase 2 | Colorectal Adenocarcinoma |
Latest
No recent events.
Follow Trifluridine Tipiracil on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.